2.61
price up icon2.76%   0.07
after-market After Hours: 2.61
loading
Bioxcel Therapeutics Inc stock is traded at $2.61, with a volume of 1.08M. It is up +2.76% in the last 24 hours and down -16.08% over the past month. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$2.54
Open:
$2.57
24h Volume:
1.08M
Relative Volume:
0.12
Market Cap:
$41.78M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.4251
EPS:
-6.14
Net Cash Flow:
$-155.03M
1W Performance:
+2.35%
1M Performance:
-16.08%
6M Performance:
+44.20%
1Y Performance:
+395.73%
1-Day Range:
Value
$2.50
$2.6499
1-Week Range:
Value
$2.42
$2.87
52-Week Range:
Value
$0.16
$8.08

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name
Name
Bioxcel Therapeutics Inc
Name
Phone
203-643-8060
Name
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Name
Employee
37
Name
Twitter
@bioxcel_tx
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
BTAI's Discussions on Twitter

Compare BTAI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BTAI
Bioxcel Therapeutics Inc
2.61 49.90M 1.38M -179.05M -155.03M -6.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.37 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.95 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.73 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
799.56 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
327.03 35.16B 4.56B -176.77M 225.30M -1.7177

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-21-24 Downgrade UBS Buy → Neutral
Aug-15-23 Downgrade Mizuho Buy → Neutral
Jul-17-23 Downgrade Guggenheim Buy → Neutral
Mar-10-23 Downgrade Jefferies Buy → Hold
Dec-01-22 Upgrade Goldman Sell → Neutral
Jul-07-22 Initiated Mizuho Buy
Apr-06-22 Reiterated BofA Securities Buy
Nov-15-21 Downgrade Goldman Neutral → Sell
Apr-09-21 Initiated Berenberg Buy
Feb-01-21 Initiated UBS Buy
Oct-30-20 Initiated Goldman Buy
Sep-02-20 Initiated Jefferies Buy
Aug-17-20 Reiterated H.C. Wainwright Buy
Jul-08-20 Reiterated H.C. Wainwright Buy
Jun-04-20 Initiated Guggenheim Buy
Apr-01-20 Initiated BofA/Merrill Buy
Feb-26-20 Reiterated H.C. Wainwright Buy
Jan-08-20 Reiterated H.C. Wainwright Buy
Nov-12-19 Initiated SunTrust Buy
View All

Bioxcel Therapeutics Inc Stock (BTAI) Latest News

pulisher
08:35 AM

Why BioXcel Therapeutics Inc. stock could see breakout soonInsider Buying & Breakout Confirmation Trade Signals - newser.com

08:35 AM
pulisher
08:29 AM

Published on: 2025-10-13 07:29:55 - newser.com

08:29 AM
pulisher
07:01 AM

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October - GlobeNewswire

07:01 AM
pulisher
07:00 AM

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation - Stock Titan

07:00 AM
pulisher
05:16 AM

Strategies to average down on BioXcel Therapeutics Inc.Trade Analysis Summary & Smart Money Movement Tracker - newser.com

05:16 AM
pulisher
Oct 12, 2025

BioXcel Therapeutics announces pricing of $7M public offering - MSN

Oct 12, 2025
pulisher
Oct 12, 2025

Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week - MSN

Oct 12, 2025
pulisher
Oct 12, 2025

BioXcel Therapeutics Inc. stock outlook for YEARShare Buyback & Low Drawdown Momentum Ideas - newser.com

Oct 12, 2025
pulisher
Oct 12, 2025

How BioXcel Therapeutics Inc. (BX20) stock reacts to stronger dollarWeekly Stock Analysis & Low Risk Profit Maximizing Plans - newser.com

Oct 12, 2025
pulisher
Oct 10, 2025

BioXcel Therapeutics Receives Positive FDA Feedback - MSN

Oct 10, 2025
pulisher
Oct 10, 2025

Sentiment analysis tools applied to BioXcel Therapeutics Inc.Weekly Investment Report & Precise Swing Trade Entry Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is BioXcel Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Movers & High Conviction Trade Alerts - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

BioXcel Therapeutics Inc. stock daily chart insights2025 Analyst Calls & Technical Confirmation Trade Alerts - newser.com

Oct 09, 2025
pulisher
Oct 07, 2025

What drives BioXcel Therapeutics Inc BX20 stock pricePrice Action Analysis & Double Or Triple Wealth - earlytimes.in

Oct 07, 2025
pulisher
Oct 06, 2025

How BioXcel Therapeutics Inc. (BX20) stock responds to bond marketJuly 2025 Outlook & Growth Focused Entry Reports - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Will BioXcel Therapeutics Inc. stock recover faster than peersQuarterly Portfolio Report & Weekly Watchlist for Hot Stocks - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Is BioXcel Therapeutics Inc. stock reversal real or fakeEarnings Recap Summary & Growth Focused Stock Pick Reports - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

BioXcel Therapeutics Inc. stock chart pattern explained2025 Market Sentiment & Community Driven Trade Alerts - newser.com

Oct 03, 2025
pulisher
Sep 30, 2025

BioXcel Investors Advance Suit Over FDA Study Compliance Issues - Bloomberg Law News

Sep 30, 2025
pulisher
Sep 28, 2025

What analysts say about BioXcel Therapeutics Inc stockMean Reversion Trades & Market Monitoring and Alerts - earlytimes.in

Sep 28, 2025
pulisher
Sep 28, 2025

BioXcel Therapeutics Inc Stock Analysis and ForecastSell Signals and Alerts & Control Your Emotions With Discipline Tools - earlytimes.in

Sep 28, 2025
pulisher
Sep 27, 2025

User - FinancialContent

Sep 27, 2025
pulisher
Sep 22, 2025

BioXcel Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada

Sep 22, 2025
pulisher
Sep 19, 2025

Volume spikes in BioXcel Therapeutics Inc. stock – what they meanJuly 2025 Trends & Intraday High Probability Alerts - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

Real time scanner hits for BioXcel Therapeutics Inc. explained2025 Volatility Report & Weekly High Return Opportunities - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

Fundamentals Check: Is BioXcel Therapeutics Inc benefiting from interest rate changesWeekly Trade Report & Technical Analysis for Trade Confirmation - خودرو بانک

Sep 19, 2025
pulisher
Sep 19, 2025

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Up 166.4% in August - MarketBeat

Sep 19, 2025
pulisher
Sep 19, 2025

ETF Watch: How cyclical is BioXcel Therapeutics Incs revenue streamAnalyst Upgrade & Risk Controlled Stock Pick Alerts - خودرو بانک

Sep 19, 2025
pulisher
Sep 18, 2025

Aug Reactions: How cyclical is BioXcel Therapeutics Incs revenue streamJuly 2025 Trends & Reliable Price Breakout Alerts - khodrobank.com

Sep 18, 2025
pulisher
Sep 18, 2025

BioXcel Therapeutics regains Nasdaq compliance after MVLS issue By Investing.com - Investing.com South Africa

Sep 18, 2025

Bioxcel Therapeutics Inc Stock (BTAI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Bioxcel Therapeutics Inc Stock (BTAI) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Mehta Vimal
CEO and President
Dec 16 '24
Sale
0.36
3,117
1,131
59,605
Steinhart Richard I
Chief Financial Officer
Dec 16 '24
Sale
0.36
577
207
20,932
Rodriguez Javier
See Remarks
Dec 16 '24
Sale
0.36
430
153
24,423
Yocca Frank
Chief Scientific Officer
Dec 16 '24
Sale
0.35
430
152
28,931
$84.73
price up icon 1.11%
$22.93
price up icon 7.40%
$32.68
price up icon 2.73%
$102.30
price up icon 0.24%
$163.94
price up icon 0.99%
biotechnology ONC
$327.03
price up icon 2.16%
Cap:     |  Volume (24h):